What is HC Wainwright’s Forecast for MBRX Q4 Earnings?

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Research analysts at HC Wainwright issued their Q4 2024 EPS estimates for shares of Moleculin Biotech in a report issued on Monday, March 3rd. HC Wainwright analyst V. Bernardino expects that the company will post earnings per share of ($1.33) for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share. HC Wainwright also issued estimates for Moleculin Biotech’s FY2025 earnings at ($3.31) EPS.

Several other research analysts also recently issued reports on the company. StockNews.com began coverage on Moleculin Biotech in a research report on Wednesday. They set a “sell” rating for the company. Maxim Group downgraded Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th.

Moleculin Biotech Trading Down 6.1 %

MBRX stock opened at $1.08 on Wednesday. The firm has a 50 day moving average of $1.52 and a 200-day moving average of $2.14. Moleculin Biotech has a 12-month low of $0.40 and a 12-month high of $10.35.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.